Cytokeratin 19 fragment (CYFRA21-1) to predict the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) harboring EGFR mutation.
Kosuke Tanaka
No relevant relationships to disclose
Akito Hata
No relevant relationships to disclose
Reiko Kaji
No relevant relationships to disclose
Shiro Fujita
No relevant relationships to disclose
Jumpei Takeshita
No relevant relationships to disclose
Takeshi Matsumoto
No relevant relationships to disclose
Kazuya Monden
No relevant relationships to disclose
Kazuma Nagata
No relevant relationships to disclose
Kyoko Otsuka
No relevant relationships to disclose
Shigeki Nanjo
No relevant relationships to disclose
Ryo Tachikawa
No relevant relationships to disclose
Kojiro Otsuka
No relevant relationships to disclose
Michio Hayashi
No relevant relationships to disclose
Keisuke Tomii
No relevant relationships to disclose
Nobuyuki Katakami
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca; Chugai Pharma